statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Lipocine Announces Financial Results for the First Quarter Ended March 31, 2024 Lipocine Announces Financial Results for the First Quarter Ended March 31, 2024 PR Newswire SALT LAKE CITY, May 9, 2024...

Lipocine Announces Financial Results for the First Quarter Ended March 31, 2024

Lipocine Announces Late Breaking Oral Presentation of Data from the Phase 2 Study of LPCN 1148 at EASL Congress 2024 Lipocine Announces Late Breaking Oral Presentation of Data from the Phase 2 Study...

Lipocine Announces Late Breaking Oral Presentation of Data from the Phase 2 Study of LPCN 1148 at EASL Congress 2024

Lipocine Announces Completion of Dosing in Pivotal Study of Postpartum Depression Candidate, LPCN 1154 Lipocine Announces Completion of Dosing in Pivotal Study of Postpartum Depression Candidate...

Lipocine Announces Completion of Dosing in Pivotal Study of Postpartum Depression Candidate, LPCN 1154

Lipocine Announces Positive LPCN 2401 Clinical Results Showing Improved Body Composition in Participants with Obesity Lipocine Announces Positive LPCN 2401 Clinical Results Showing Improved Body...

Lipocine Announces Positive LPCN 2401 Clinical Results Showing Improved Body Composition in Participants with Obesity

StockNews.com initiated coverage on shares of Lipocine (NASDAQ:LPCN - Free Report) in a research note released on Wednesday. The firm issued a sell rating on the specialty pharmaceutical company's...

StockNews.com Initiates Coverage on Lipocine (NASDAQ:LPCN)

StockNews.com began coverage on shares of Lipocine (NASDAQ:LPCN - Free Report) in a research report released on Wednesday morning. The firm issued a sell rating on the specialty pharmaceutical...

StockNews.com started coverage on shares of Lipocine (NASDAQ:LPCN  Free Report) in a report published on Tuesday morning. The brokerage issued a sell rating on the specialty pharmaceutical...

StockNews.com Begins Coverage on Lipocine (NASDAQ:LPCN)

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Lipocine's LPCN 1148 shows positive results in Phase 2 cirrhosis study

Lipocine Announces Positive Week 52 Results from LPCN 1148 Phase 2 Study in Patients with Cirrhosis Lipocine Announces Positive Week 52 Results from LPCN 1148 Phase 2 Study in Patients with Cirrhosis...

Lipocine Announces Positive Week 52 Results from LPCN 1148 Phase 2 Study in Patients with Cirrhosis

Lipocine announces first cohort dosed in LPCN 1154

Lipocine, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of the delivery of drugs using proprietary delivery technology. It offers TLANDO, an oral testosterone replacement therapy. The company was founded on October 13, 2011 and is headquartered in Salt Lake City, UT.

Watchers	14,795
52-Wk Low	$2.31
52-Wk High	$7.15

Volume	31,968.00
52-Wk High	$7.15
52-Wk Low	$2.31

LPCN Lipocine Inc

About

Feed

News

Earnings

Fundamentals